Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 14/20 | 0.57 |
| ▸ | TP53 | P04637 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | PTGIR | P43119 | 1/20 | 0.50 |
| ▸ | CASP9 | P55211 | 1/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045613 | 0.94 | TP53 (0.53) | DGAT1TP53LMNACYP2C9EGFR | |
| SCHEMBL9984828 | 0.92 | DGAT1 (0.60) | DGAT1TP53CYP2C9EGFRINSR | |
| SCHEMBL9985010 | 0.91 | DGAT1 (0.68) | DGAT1TP53CYP2C9MAPTTHRB | |
| SCHEMBL9985427 | 0.90 | DGAT1 (0.58) | DGAT1TP53LMNACYP2C9EGFR | |
| SCHEMBL12045660 | 0.88 | TP53 (0.52) | DGAT1TP53LMNACYP2C9EGFR | |
| SCHEMBL9985031 | 0.88 | DGAT1 (0.69) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL9985397 | 0.88 | DGAT1 (0.61) | DGAT1TP53LMNACYP2C9EGFR | |
| SCHEMBL9985440 | 0.87 | DGAT1 (0.72) | DGAT1TP53CYP2C9MAPTTHRB | |
| SCHEMBL9984513 | 0.86 | DGAT1 (0.67) | DGAT1TP53LMNACYP2C9MAPT | |
| SCHEMBL462169 | 0.86 | DGAT1 (0.57) | DGAT1TP53LMNACYP2C9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885TP53 4507/4885LMNA 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.